OmniAb to Participate in Three Upcoming Investor Conferences
07 2월 2023 - 10:00PM
Business Wire
OmniAb, Inc. (NASDAQ: OABI) today announced that
management will be participating in three upcoming investor
conferences.
- SVB Securities Global Biopharma Conference, February 14-16,
2023. Management will be participating in a virtual fireside
chat on Wednesday, February 15th at 11:20 a.m. Eastern time and
will be hosting one-on-one virtual meetings with investors.
- Cowen 43rd Annual Health Care Conference, March 6-8,
2023 at the Boston Marriott Copley Place. Management will be
presenting a corporate overview on Wednesday, March 8th at 9:50
a.m. Eastern time and will be hosting one-on-one meetings with
investors. The presentation will be webcast live and available for
replay in the Investors section of OmniAb’s website by clicking
here.
- 35th Annual Roth Conference, March 12-14, 2023 at The
Ritz-Carlton Laguna Niguel. Management will be hosting
one-on-one meetings with investors.
About OmniAb® OmniAb’s discovery platform provides
pharmaceutical industry partners access to diverse antibody
repertoires and high-throughput screening technologies to enable
discovery of next-generation therapeutics. At the heart of the
OmniAb platform is the Biological Intelligence™ (BI) of our
proprietary transgenic animals, including OmniRat®,
OmniChicken® and OmniMouse® that have been
genetically modified to generate antibodies with human sequences to
facilitate development of human therapeutic candidates.
OmniFlic® (transgenic rat) and OmniClic® (transgenic
chicken) address industry needs for bispecific antibody
applications though a common light chain approach, and OmniTaur™
features unique structural attributes of cow antibodies for complex
targets. We believe the OmniAb animals comprise the most diverse
host systems available in the industry and they are optimally
leveraged through computational antigen design and immunization
methods, paired with high-throughput single B cell phenotypic
screening and mining of next-generation sequencing datasets with
custom algorithms to identify fully human antibodies with superior
performance and developability characteristics. An established core
competency focused on ion channels and transporters further
differentiates our technology and creates opportunities in emerging
target classes. OmniAb antibodies have been leveraged across
modalities, including bispecific antibodies, antibody-drug
conjugates and others. The OmniAb suite of technologies span from
BI-powered repertoire generation to cutting edge antibody discovery
and optimization offering a highly efficient and customizable
end-to-end solution for the growing discovery needs of the global
pharmaceutical industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230207005191/en/
OmniAb, Inc. investors@OmniAb.com Twitter @OmniAbTech (510)
250-7801
LHA Investor Relations Yvonne Briggs ybriggs@lhai.com (310)
691-7100
OmniAb (NASDAQ:OABI)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
OmniAb (NASDAQ:OABI)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024